retatrutide side effects libido experimental weight-loss drug and concerns Retatrutide – Obesity, Type 2

The novel peptide is biased towards GLP-1R agonism versus GCGR with a 3-4 fold reduced potency at the GLP-1R compared to native GLP-1 and around an 8-fold reduced potency at the GCGR compared to native glucagon

1,961 adults with obesity or overweight and at least one weight-related comorbidity but without diabetes

The majority of people who quit do so when the dose goes up

These beneficial fats signal to your small intestine that nutrient-dense food has arrived, which slows down the rate at which your stomach empties and sends a sustained all is well signal to your brain

The honest answer from management would be: we dont know the full impact yet, but 16% of households having a user, 8% declines in fast food spending, and the fastest-growing prescription category in the country is not something we can ignore.

It is crucial to consult a healthcare professional before considering off-label use to understand the potential risks